Skip to main navigation Skip to search Skip to main content

PolyIC GE11 polyplex inhibits EGFR-overexpressing tumors

  • Galith Abourbeh
  • , Alexei Shir
  • , Eyal Mishani
  • , Manfred Ogris
  • , Wolfgang Rödl
  • , Ernst Wagner
  • , Alexander Levitzki*
  • *Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

57 Scopus citations

Abstract

Phage display has identified the dodecapeptide YHWYGYTPQNVI (GE11) as a ligand that binds to the epidermal growth factor receptor (EGFR) but does not activate the receptor. Here, we compare the EGFR binding affinities of GE11, EGF, and their polyethyleneimine-polyethyleneglycol (PEI-PEG) conjugates. We found that although GE11 by itself does not exhibit measurable affinity to the EGFR, tethering it to PEI-PEG increases its affinity markedly, and complex formation with polyinosine/cytosine (polyIC) further enhances the affinity to the submicromolar range. PolyIC/PPGE11 has a similar strong antitumor effect against EGFR overexpressing tumors in vitro and in vivo, as polyIC/ polyethyleneimine-polyetheleneglycol-EGF (polyIC/PP-EGF). Absence of EGFR activation, as previously shown by us and easier production of GE11 and GE11 conjugates, confer polyIC/PPGE11 a significant advantage over similar EGF-based polyplexes as a potential therapy of EGFR overexpressing tumors.

Original languageEnglish
Pages (from-to)324-330
Number of pages7
JournalIUBMB Life
Volume64
Issue number4
DOIs
StatePublished - Apr 2012

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • EGFR
  • GE11
  • polyIC

Fingerprint

Dive into the research topics of 'PolyIC GE11 polyplex inhibits EGFR-overexpressing tumors'. Together they form a unique fingerprint.

Cite this